Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Inclusion Criteria:

* Eligible to undergo autologous transplantation.
* Diagnosis of NHL, HD or MM \[patients with plasma cell leukemia or other leukemias including chronic lymphocytic leukemia (CLL), are excluded\].
* In the last collection attempt prior to entry into this trial, the patient has failed to collect 0.8x10\^6 cells/kg in at least 2 apheresis sessions or 2x10\^6 cells/kg in 4 apheresis sessions using a mobilization regimen of chemotherapy, with or without G-CSF.
* A minimum of a 7 day interval between last collection attempt and randomization.
* Cardiac, pulmonary and renal function deemed clinically adequate to be able to undergo mobilization and transplant.
* Performance status, Eastern Cooperative Oncology Group (ECOG) of 0 or 1
* ≥ 21 days between the last cycle of chemotherapy and randomization (thalidomide, dexamethasone, and other corticosteroids, Rituxan® and Velcade® are not considered prior chemotherapy for the purpose of this study).
* The patient has recovered from all acute toxic effects of prior chemotherapy.
* WBC ≥ 2.5x10\^9/l.
* Absolute neutrophil count ≥ 1.5x10\^9/l.
* Platelet count ≥ 75x10\^9/l.
* Adequate renal function as demonstrated by serum creatine ≤ or equal to 2.2 mg/dl or creatinine clearance (24 hr urine collection)≥ 60 ml/min
* Serum Glutamate Oxaloacetate Transaminase (SGOT), Serum Glutamate Pyruvate Transaminase (SGPT) and total bilirubin ≤ 2.5 x upper limit of normal (ULN).
* Signed informed consent.
* All patients must agree to use a highly effective method of contraception (including both female patients of child-bearing potential and male patients with child-bearing potential partners). Effective birth control includes: a) birth control pills, depo-progesterone, or an IUD PLUS one barrier method, or b) two barrier methods. Effective barrier methods are: male and female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). For patients using hormonal contraceptive method, information about any interaction of MAD3100 with hormonal contraceptives is not known.

Exclusion Criteria:

* A co-morbid condition which, in the view of the Investigators, renders the patient at high risk from treatment complications.
* A residual acute medical condition resulting from prior chemotherapy.
* Received thalidomide, dexamethasone or corticosteroids, Rituxan® and Velcade® within 7 days prior to randomization.
* Brain metastases or carcinomatous meningitis.
* Active acute or chronic infection or anti-infective therapy within 1 week prior to randomization.
* Fever (temperature ≥ 38 degrees celsius).
* Hypercalcemia (≥ 1mg/dl above the ULN).
* Known to be HIV-positive.
* Pregnant and nursing females.
* Patient unwilling to implement adequate birth control (including both female patients of child-bearing potential and male patients with child-bearing potential partners).
* Patients who previously received experimental therapy within 4 weeks of randomization or who are currently enrolled in another experimental protocol during the Mobilization phase.
* Patients who have failed previous collection attempt within 7 days or less from randomization.